Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems

Abuhassan, Qamar and Khadra, Ibrahim and Pyper, Kate and Augustijns, Patrick and Brouwers, Joachim and Halbert, Gavin W. (2022) Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems. European Journal of Pharmaceutics and Biopharmaceutics, 170. pp. 160-169. ISSN 0939-6411 (https://doi.org/10.1016/j.ejpb.2021.12.006)

[thumbnail of Abuhassan-etal-EJPB-2021-Fasted-intestinal-solubility-limits-and-distributions]
Preview
Text. Filename: Abuhassan_etal_EJPB_2021_Fasted_intestinal_solubility_limits_and_distributions.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (902kB)| Preview

Abstract

After oral administration, a drug’s solubility in intestinal fluid is an important parameter influencing bioavailability and if the value is known it can be applied to estimate multiple biopharmaceutical parameters including the solubility limited absorbable dose. Current in vitro measurements may utilise fasted human intestinal fluid (HIF) or simulated intestinal fluid (SIF) to provide an intestinal solubility value. This single point value is limited since its position in relation to the fasted intestinal solubility envelope is unknown. In this study we have applied a nine point fasted equilibrium solubility determination in SIF, based on a multi-dimensional analysis of fasted human intestinal fluid composition, to seven drugs that were previously utilised to investigate the developability classification system (ibuprofen, mefenamic acid, furosemide, dipyridamole, griseofulvin, paracetamol and acyclovir). The resulting fasted equilibrium solubility envelope encompasses literature solubility values in both HIF and SIF indicating that it measures the same solubility space as current approaches with solubility behaviour consistent with previous SIF design of experiment studies. In addition, it identifies that three drugs (griseofulvin, paracetamol and acyclovir) have a very narrow solubility range, a feature that single point solubility approaches would miss. The measured mid-point solubility value is statistically equivalent to the value determined with the original fasted simulated intestinal fluid recipe, further indicating similarity and that existing literature results could be utilised as a direct comparison. Since the multi-dimensional approach covered greater than ninety percent of the variability in fasted intestinal fluid composition, the measured maximum and minimum equilibrium solubility values should represent the extremes of fasted intestinal solubility and provide a range. The seven drugs all display different solubility ranges and behaviours, a result also consistent with previous studies. The dose/solubility ratio for each measurement point can be plotted using the developability classification system to highlight individual drug behaviours. The lowest solubility represents a worst-case scenario which may be useful in risk-based quality by design biopharmaceutical calculations than the mid-point value. The method also permits a dose/solubility ratio frequency distribution determination for the solubility envelope which permits further risk-based refinement, especially where the drug crosses a classification boundary. This novel approach therefore provides greater in vitro detail with respect to possible biopharmaceutical performance in vivo and an improved ability to apply risk-based analysis to biopharmaceutical performance. Further studies will be required to expand the number of drugs measured and link the in vitro measurements to in vivo results.

ORCID iDs

Abuhassan, Qamar, Khadra, Ibrahim, Pyper, Kate ORCID logoORCID: https://orcid.org/0000-0002-7782-1048, Augustijns, Patrick, Brouwers, Joachim and Halbert, Gavin W.;